Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - levetiracetam, quantity: 1000 mg - tablet, film coated - excipient ingredients: maize starch; povidone; purified talc; magnesium stearate; colloidal anhydrous silica; titanium dioxide; hypromellose; macrogol 400 - it is indicated for:,? use in epileptic patients aged 4 years and older, initially as add on therapy, in the treatment of partial onset seizures with or without secondary generalisation,,? monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy.,? add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme),and,? add on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (ige).

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - levetiracetam, quantity: 250 mg - tablet, film coated - excipient ingredients: povidone; colloidal anhydrous silica; maize starch; purified talc; magnesium stearate; titanium dioxide; hypromellose; indigo carmine; macrogol 4000 - it is indicated for:,? use in epileptic patients aged 4 years and older, initially as add on therapy, in the treatment of partial onset seizures with or without secondary generalisation,,? monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy.,? add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme),and,? add on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (ige).

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - levetiracetam, quantity: 750 mg - tablet, film coated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; povidone; maize starch; purified talc; titanium dioxide; hypromellose; indigo carmine; sunset yellow fcf; iron oxide red; macrogol 4000 - it is indicated for:,? use in epileptic patients aged 4 years and older, initially as add on therapy, in the treatment of partial onset seizures with or without secondary generalisation,,? monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy.,? add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme),and,? add on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (ige).

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - levetiracetam, quantity: 500 mg - tablet, film coated - excipient ingredients: povidone; purified talc; magnesium stearate; colloidal anhydrous silica; maize starch; titanium dioxide; hypromellose; iron oxide yellow; macrogol 4000 - it is indicated for:,? use in epileptic patients aged 4 years and older, initially as add on therapy, in the treatment of partial onset seizures with or without secondary generalisation,,? monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy.,? add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme),and,? add on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (ige).

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - voriconazole, quantity: 40 mg/ml - suspension, powder for - excipient ingredients: titanium dioxide; sodium benzoate; citric acid; colloidal anhydrous silica; sodium citrate dihydrate; sucrose; xanthan gum; flavour - vfend is indicated for treatment of the following fungal infections: invasive aspergillosis. serious candida infections (including c. krusei), including oesophageal and systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia). serious fungal infections caused by scedosporium spp and fusarium spp. other serious fungal infections, in patients intolerant of, or refractory to, other therapy. *prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - mesalazine, quantity: 1000 mg - enema - excipient ingredients: disodium edetate; sodium acetate; purified water; sodium metabisulfite; hydrochloric acid - for the treatment of ulcerative proctosigmoiditis and/or treatment of left-sided ulcerative colitis.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - soya oil, quantity: 0 qs; olive oil, quantity: 0 qs - injection, emulsion - excipient ingredients: water for injections; ascorbyl palmitate; glycerol; sodium oleate; sodium hydroxide; egg lecithin - parenteral nutrition when oral or enteral nutrition is impossible, insufficient or contraindicated.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - olopatadine hydrochloride, quantity: 1.11 mg/ml - eye drops, solution - excipient ingredients: purified water; dibasic sodium phosphate dodecahydrate; hydrochloric acid; sodium chloride; benzalkonium chloride; sodium hydroxide - indicated for the treatment of signs and symptoms of seasonal allergic conjuctivitis. treatment may be maintained for up to 14 weeks, if considered necessary.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - brimonidine tartrate, quantity: 2 mg/ml - eye drops, solution - excipient ingredients: polyvinyl alcohol; benzalkonium chloride; citric acid; hydrochloric acid; sodium citrate dihydrate; sodium chloride; sodium hydroxide; purified water - indications:enidin eye drops are effective as monotherapy for lowering intraocular pressure in patients with chronic open-angle glaucoma or ocular hypertension in whom (beta symbol)-blockers are not tolerated or are contraindicated. indications as at 7 december 1999: enidin eye drops are effective in lowering elevated intraocular pressure in patients with chronic open angle glaucoma or ocular hypertension.enidin eye drops can be used in the treatment of glaucoma either as monotherapy or in combination with topical beta-blockers.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

iotech pty ltd - sodium amidotrizoate, quantity: 370.5 mg/ml - oral liquid, solution - excipient ingredients: sorbitol; acesulfame potassium; quinoline yellow; methyl hydroxybenzoate; citric acid; purified water; flavour - ioscan is a contrast medium for computerised axial tomograpghy examination of the gastrointestinal tract. it should be made up with water prior to use, and administered orally. it is indicated primarily for use when barium sulphate is not appropriate.